MedTrace Logo

Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide

NCT07021859 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-08-06

No results posted yet for this study

Summary

Calcitonin gene-related peptide (CGRP) is a key neuropeptide in migraine pathophysiology and treatment. This study investigates whether CGRP administration can trigger aura in individuals with a diagnosis of migraine with aura.

Conditions

  • Migraine Aura
  • Migraine With Aura

Interventions

DRUG

Calcitonin-gene related peptide (CGRP)

The participants will receive a continuous intravenous infusion of 1.5 μg/min of CGRP over 60 minutes.

DRUG

Placebo

The participants will receive a continuous intravenous infusion of 60 mL of placebo (isotonic saline) over 60 minutes.

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-27
Primary Completion
2026-06-01
Completion
2026-12-30

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07021859 on ClinicalTrials.gov